$RGLS
Regulus Therapeutics Inc.

2013 Q1 Form 10-Q Financial Statement

#000119312513220102 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $3.238M $3.344M
YoY Change -3.17% 1.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.910M $920.0K
YoY Change 107.61%
% of Gross Profit
Research & Development $6.883M $4.603M
YoY Change 49.53%
% of Gross Profit
Depreciation & Amortization $289.0K $225.0K
YoY Change 28.44%
% of Gross Profit
Operating Expenses $8.788M $5.525M
YoY Change 59.06% 1.19%
Operating Profit -$5.550M -$2.180M
YoY Change 154.59%
Interest Expense $70.00K $93.00K
YoY Change -24.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.239M -$2.246M
YoY Change 222.31%
Income Tax -$10.00K $1.000K
% Of Pretax Income
Net Earnings -$7.229M -$2.248M
YoY Change 221.57% -1.79%
Net Earnings / Revenue -223.26% -67.22%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20 -$112.5M
COMMON SHARES
Basic Shares Outstanding 35.88M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.70M
YoY Change
Cash & Equivalents $17.82M $10.10M
Short-Term Investments $72.90M
Other Short-Term Assets $1.100M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $91.77M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $3.892M
YoY Change
Goodwill
YoY Change
Intangibles $1.176M
YoY Change
Long-Term Investments
YoY Change
Other Assets $190.0K
YoY Change
Total Long-Term Assets $5.258M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $91.77M
Total Long-Term Assets $5.258M
Total Assets $97.03M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $398.0K
YoY Change
Accrued Expenses $2.335M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.69M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $11.90M
YoY Change
Other Long-Term Liabilities $804.0K
YoY Change
Total Long-Term Liabilities $804.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.69M
Total Long-Term Liabilities $804.0K
Total Liabilities $41.16M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$67.65M
YoY Change
Common Stock $36.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.87M
YoY Change
Total Liabilities & Shareholders Equity $97.03M
YoY Change

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$7.229M -$2.248M
YoY Change 221.57% -1.79%
Depreciation, Depletion And Amortization $289.0K $225.0K
YoY Change 28.44%
Cash From Operating Activities -$7.155M -$5.128M
YoY Change 39.53%
INVESTING ACTIVITIES
Capital Expenditures $77.00K $354.0K
YoY Change -78.25%
Acquisitions
YoY Change
Other Investing Activities -$15.67M $6.480M
YoY Change -341.82%
Cash From Investing Activities -$15.75M $6.123M
YoY Change -357.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $85.00K $33.00K
YoY Change 157.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 173.0K -74.00K
YoY Change -333.78%
NET CHANGE
Cash From Operating Activities -7.155M -5.128M
Cash From Investing Activities -15.75M 6.123M
Cash From Financing Activities 173.0K -74.00K
Net Change In Cash -22.73M 921.0K
YoY Change -2567.97%
FREE CASH FLOW
Cash From Operating Activities -$7.155M -$5.128M
Capital Expenditures $77.00K $354.0K
Free Cash Flow -$7.232M -$5.482M
YoY Change 31.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
5000000
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36007278 shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10096000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1054000
CY2013Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
90285000
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
190000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
55867000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
759000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35965371 shares
CY2013Q1 us-gaap Liabilities
Liabilities
41160000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
398000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9201000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
804000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67648000
CY2013Q1 us-gaap Assets
Assets
97027000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.24
CY2013Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
5400000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97027000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17822000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35965371 shares
CY2013Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1176000
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-37000
CY2013Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8793796 shares
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2335000
CY2013Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
11895000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12693000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4743000 shares
CY2013Q1 us-gaap Short Term Investments
ShortTermInvestments
72893000
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
36000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15768000
CY2013Q1 us-gaap Assets Current
AssetsCurrent
91769000
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3892000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
123516000
CY2013Q1 rgls Cash And Cash Equivalents And Short Term Investments Fair Value
CashAndCashEquivalentsAndShortTermInvestmentsFairValue
72893000
CY2013Q1 rgls Cash And Cash Equivalents And Short Term Investments At Amortized Cost
CashAndCashEquivalentsAndShortTermInvestmentsAtAmortizedCost
72910000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9175000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
829000
CY2012Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
96911000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
62093000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1348000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35831808 shares
CY2012Q4 us-gaap Liabilities
Liabilities
41425000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
311000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10451000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40552000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35831808 shares
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1154000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
767000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60419000
CY2012Q4 us-gaap Assets
Assets
103518000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.11
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103518000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2012Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
10134000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12768000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4720000 shares
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
57548000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17756000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
98929000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3310000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122528000
CY2012Q4 rgls Cash And Cash Equivalents And Short Term Investments Fair Value
CashAndCashEquivalentsAndShortTermInvestmentsFairValue
57548000
CY2012Q4 rgls Cash And Cash Equivalents And Short Term Investments At Amortized Cost
CashAndCashEquivalentsAndShortTermInvestmentsAtAmortizedCost
57590000
CY2012 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
49000
CY2012 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
7000
CY2013Q1 dei Trading Symbol
TradingSymbol
RGLS
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
66000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5550000
CY2013Q1 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Deferred Revenue</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.</font></p> </div>
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86000
CY2013Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0030 pure
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
201000
CY2013Q1 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.70 pure
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2013Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7214000
CY2013Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
776000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3238000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.09
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
77000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
289000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
787000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.88
CY2013Q1 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
28000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-7229000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
107000 shares
CY2013Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1256232 shares
CY2013Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
28000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7155000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15748000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22730000
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-588000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1905000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
225000
CY2013Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
72000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6883000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
8788000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2013Q1 us-gaap Revenues
Revenues
3238000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
787000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7239000
CY2013Q1 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
11000
CY2013Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
2430000
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
27000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35872606000 shares
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3483910 shares
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-7229000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
130000 shares
CY2013Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
CY2013Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18074000
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></p> </div>
CY2013Q1 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.085 pure
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
822000
CY2013Q1 rgls Amounts Accrued For Patent Expenditures
AmountsAccruedForPatentExpenditures
15000
CY2013Q1 rgls Gain Loss From Valuation Of Convertible Note Payable
GainLossFromValuationOfConvertibleNotePayable
-1761000
CY2013Q1 rgls Net Amortization Of Premiums On Investment Securities
NetAmortizationOfPremiumsOnInvestmentSecurities
324000
CY2012Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
105000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2180000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2181000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
225000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
113000
CY2012Q1 us-gaap Profit Loss
ProfitLoss
-2247000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.06
CY2012Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
107000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5128000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6123000
CY2012Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
206000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3159000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
921000
CY2012Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-165000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
921000
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-101000
CY2012Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
27000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4603000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-74000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
5524000
CY2012Q1 us-gaap Revenues
Revenues
3344000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
113000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2246000
CY2012Q1 us-gaap Interest Paid
InterestPaid
12000
CY2012Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
22000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
171998000 shares
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15918774 shares
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-2247000
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2012Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4612000
CY2012Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
11111000
CY2012Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66000
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-237000
CY2012Q1 us-gaap Interest Expense
InterestExpense
93000
CY2012Q1 rgls Net Amortization Of Premiums On Investment Securities
NetAmortizationOfPremiumsOnInvestmentSecurities
124000

Files In Submission

Name View Source Status
0001193125-13-220102-index-headers.html Edgar Link pending
0001193125-13-220102-index.html Edgar Link pending
0001193125-13-220102.txt Edgar Link pending
0001193125-13-220102-xbrl.zip Edgar Link pending
d501637d10q.htm Edgar Link pending
d501637dex311.htm Edgar Link pending
d501637dex312.htm Edgar Link pending
d501637dex321.htm Edgar Link pending
d501637dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20130331.xml Edgar Link completed
rgls-20130331.xsd Edgar Link pending
rgls-20130331_cal.xml Edgar Link unprocessable
rgls-20130331_def.xml Edgar Link unprocessable
rgls-20130331_lab.xml Edgar Link unprocessable
rgls-20130331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending